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Discovery and Validation of Methylation Biomarkers for 
Ulcerative Colitis Associated Neoplasia
Andrew D. Beggs, FRCS(Gen), PhD,* Jonathan James, PhD,* Germaine Caldwell, PhD,*  
Toby Prout, MSci,* Mark P. Dilworth, FRCS(Gen), MD,* Phillipe Taniere, MD, PhD,* Tariq Iqbal, FRCP, MD,*  
Dion G. Morton, FRCS, MD,*,and Glenn Matthews, PhD*
Background and aims: Ulcerative colitis (UC) is associated with a higher background risk of dysplasia and/or neoplasia due to chronic inflam-
mation. There exist few biomarkers for identification of patients with dysplasia, and targeted biopsies in this group of patients are inaccurate in 
reliably identifying dysplasia. We aimed to examine the epigenome of UC dysplasia and to identify and validate potential biomarkers
Methods: Colonic samples from patients with UC-associated dysplasia or neoplasia underwent epigenome-wide analysis on the Illumina 450K 
methylation array. Markers were validated by bisulphite pyrosequencing on a secondary validation cohort and accuracy calculated using logistic 
regression and receiver-operator curves.
Results: Twelve samples from 4 patients underwent methylation array analysis and 6 markers (GNG7, VAV3, KIF5C, PIK3R5, TUBB6, and 
ZNF583) were taken forward for secondary validation on a cohort of 71 colonic biopsy samples consisting of normal uninflamed mucosa from 
control patients, acute and chronic colitis, “field” mucosa in patients with dysplasia/neoplasia, dysplasia, and neoplasia. Methylation in the 
beta-tubulin TUBB6 correlated with the presence of dysplasia (P < 0.0001) and accurately discriminated between dysplasia and nondysplastic 
tissue, even in the apparently normal field mucosa downstream from dysplastic lesions (AUC 0.84, 95% CI 0.81–0.87).
Conclusions: Methylation in TUBB6 is a potential biomarker for UC- associated dysplasia. Further validation is needed and is ongoing as part 
of the ENDCAP-C study.
Key Words:  ulcerative colitis associated dysplasia, methylation, biomarkers
INTRODUCTION
Ulcerative colitis (UC) is a systemic autoimmune inflam-
matory disorder, primarily targeted at the colon and rectum, 
leading to widespread transmural mucosal inflammation. It 
is associated with an increased risk of cancer1 and a recent 
meta-analysis demonstrated that in population-based cohorts, 
cancer risk increases 2.4-fold, with male sex, young age at diag-
nosis, and extensive colitis further increasing the risk.2
UC-associated cancers arise in a similar fashion to spo-
radic carcinomas, however, they arise through an inflamma-
tion-dysplasia-carcinoma sequence3, 4 that leads to accelerated 
carcinogenesis. The risk of cancer increases exponentially with 
duration of disease and has led to screening guidelines that 
take account of duration of symptoms.
The British Society of Gastroenterology guidelines5 
recommend that a single surveillance colonoscopy should be 
performed within 8 years of onset of symptoms, followed by 
5 yearly in the second decade, 3 yearly in the third decade, and 
yearly in the fourth decade. It also is recommended that as part 
of these colonoscopies approximately 2–4 serial biopsies be 
taken every 5-10 cm within the colon. This represents a consid-
erable burden for the screening endoscopist, although technol-
ogies such as chromoendoscopy6 and narrow band imaging7 
have been used, to varying degrees of success. The use of ran-
dom biopsies, even where they are taken frequently, may also 
reduce the chance of successful detection of UC-associated 
dysplasia or cancer.8
A need exists for biomarkers that can reliably detect 
UC-associated dysplasia and cancer within the colon as part 
of a screening program.9 A  number of different approaches 
and technologies have been used to find an effective biomarker. 
Bronner et al10 utilised fluorescent in situ hybridisation (FISH) 
of fresh frozen colonic biopsy specimens, finding 100% sensi-
tivity and 92% specificity in discriminating patients who went 
on to develop neoplasia from those who did not.
Leedham et  al11 investigated mutational spectrum in 
UC-associated dysplasia and found that TP53 mutation was 
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most frequent, with KRAS driver mutations being found in a 
subset of tumours. They also demonstrated that the lesions seen 
in UC-associated neoplasia were monoclonal in origin, with a 
driver mutation leading to multiple clones possessing the same 
mutation. Risques et  al found that shortening of telomeres, 
associated with cellular senescence12 in a field effect, seemed to 
indicate which areas of UC-associated dysplasia were likely to 
progress to cancer.
Other genetic markers for high risk UC-associated dys-
plasia that have been studied include chromosomal instability 
and microsatellite instability. Rubin et al13 studied the rates of 
aneuploidy in patients with UC-associated dysplasia, finding 
an association between aneuploidy in biopsy specimens and 
progression to neoplasia, however this association has not been 
consistently reported by other studies.14 Microsatellite instabil-
ity (MSI) also has been studied as a potential marker, however 
no strong correlations between MSI and progression to neopla-
sia has been found.15, 16
It is obvious that current markers for high risk 
UC-associated neoplasia are lacking in accuracy. Analysis 
of methylation, an epigenetic modification to DNA, has sev-
eral advantages. Firstly, DNA methylation is a stable change 
that is detectable in formalin fixed, paraffin-embedded biopsy 
samples.17 Secondly, disease associated regions of methylation 
change tend to occur in longer stretches of DNA than point 
mutations18 and in fields of change within affected tissues, 
allowing easier assay design and less need for targeted biopsies.
We therefore aimed to study the changes seen in DNA 
methylation in high risk UC-associated dysplasia to develop 
potential biomarkers for this disease.
METHODS
Patients and Ethical Approval
Patients were recruited from the University Hospital 
Birmingham inflammatory bowel disease (IBD) clinic using 
an in-house IBD database to identify patients. For patients 
with neoplasia, patients were included in the study if  they 
had UC of  greater than 8  years in duration, had devel-
oped UC-associated neoplasia, had a proctocolectomy for 
UC-associated neoplasia with frozen material taken, and 
had archival histological material (tumor and paired normal) 
available for analysis. Patients were excluded if  they did not 
have histological material available for analysis or the dur-
ation of  their disease was less than 8 years. Acute colitis was 
defined as a first presentation of  colitis, and chronic colitis 
was defined as colitis of  greater than 8 years in duration. All 
patients with both “acute” and “chronic” colitis were sampled 
when they were receiving (at the most) only 5-ASA therapy for 
their colitis, rather than immunosuppressive agents that may 
bias methylation measurements.
Patients with chronic inflammation caused by UC with-
out the development of neoplasia also were recruited to serve 
as nonneoplastic but inflamed controls. This was to exclude 
biomarkers that may have been associated with inflammation 
rather than driving tumoriogenesis.
The study was carried out with full ethical approval 
from the South Birmingham Research Ethics Committee (08/
H1207/104).
Sample Collection, Extraction, and 
Quantification
Tissue blocks were retrieved from histology archives, 
and associated H&E sections were reviewed by a consultant 
histopathologist (Phillipe Taniere) to ensure accuracy of his-
tological diagnosis. For the discovery set, frozen tissue was 
obtained at the time of proctocolectomy by opening the speci-
men and representative samples of tumor and normal mucosa 
were obtained. Normal mucosa was obtained at the maximal 
possible distance from the tumor specimen. Histological type 
was confirmed by frozen sectioning, and all tumor material 
was confirmed to be adenocarcinoma. Dysplasia was catego-
rized according to the methodology of Riddell et al19 as either 
“high grade” or “low grade”. This was snap frozen in liquid 
nitrogen then stored at -80 C until needed. For archival spec-
imens, blocks were sectioned into 10μM sections and placed 
on slides. Needle macrodissection using white light micros-
copy comparing to a representative H&E section was used to 
enhance for tumor content. For DNA extraction of both sets, 
samples were immersed in 300 uL of buffer ATL (Qiagen Ltd, 
Manchester, UK) and 20μL of 20mg/μL Proteinase K (VWR 
Jencons, Lutterworh,UK). Samples were incubated overnight 
in a tissue oven, spun down to form a wax plug that was then 
punctured (for FFPE samples), and the lysate retrieved. This 
was cleaned and purified using a Qiagen DNeasy Blood & 
Tissue kit (Qiagen Ltd, Manchester UK). Extracted DNA was 
quantified for purity using a Nanodrop ND-2000 spectropho-
tometer and for quantity using a Qubit fluorimeter. If  samples 
did not pass a quality threshold of A260/280 >1.8 they were 
reextracted. DNA was stored at -80 C until ready for use.
Methylation Microarray Discovery
To quantify methylation across the whole genome, the 
Illumina HumanMethylation450 array system was used on 
fresh tissue from the first part of the study. This is an oligo-
nucleotide-based microarray platform that has over 458,000 
probes targeted at CpG dinucleotides selected by an interna-
tional consortium of epigenetics researchers to cover gene pro-
moter regions, differentially methylated regions (DMRs), and 
other regions of interest.
One microgram of extracted DNA was bisulphite con-
verted using the Zymo EZ-DNA Methylation kit with a 
modified protocol suitable for use on Illumina microarrays. 
A  standard amplification, hybridization, labeling, and wash 
procedure was carried out by the Core Genomics Facility at 
the Wellcome Trust Centre for Human Genetics, University of 
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Oxford. Microarrays were scanned on an Illumina iScan array 
scanner and detected intensities were converted to IDAT files 
and exported for further use.
Exported intensity data were analyzed using a com-
bination of limma/Bioconductor and the ChAMP pipeline 
for methylation array analysis.20 Data were imported into R 
2.15.1 and were filtered to remove all probes that had failed 
the detection threshold (P > 0.05). Quality control plots were 
also produced and any samples failing lllumina standard QC 
were excluded. Probes were then normalized to adjust for Type 
2 bias using BMIQ normalization, underwent SVD identifica-
tion for components of variation, and batch correction using 
COMBAT. Top differentially methylated probes were called 
using a 3 level regression and eBayes shrinkage of moderated 
t-statistics using limma and DMRs called using DMRHunter. 
Copy number variation was called using the copy number func-
tion of the ChAMP package.
Validation
To provide validation samples, the IBD database was 
interrogated to provide a further cohort of samples for vali-
dation using bisulphite pyrosequencing. Targets for validation 
were identified from the top hits from the CHaMP analysis. The 
Illumina probe identifier for each hit was retrieved and genomic 
coordinates for the relevant CpG dinucleotide were identified 
from the HumanMethylation450 manifest file.
A primer set for bisulphite pyrosequencing was 
designed flanking the CpG dinucleotide of  interest using 
Qiagen PyroMark 2.0 software using standard conditions. 
If  a primer set could not be designed using standard con-
ditions, the relevant conditions (Tm, amplicon length) were 
adjusted until a set could be designed. A maximum amplicon 
length of  250 bp was set as the validation samples originated 
from FFPE samples and our previous experiences in FFPE 
primer design had demonstrated that this was the maximum 
achievable primer sequence for this type of  sample. Designed 
primers were biotinylated in either the forward or reverse dir-
ection, depending on design characteristics and primers were 
obtained from Sigma-Aldrich (Primer sequences available on 
request).
Obtained forward and reverse primers were diluted 
to 20 uM and used in a gradient PCR reaction using the 
Qiagen Pyromark PCR kit under standard conditions in a 
reaction volume of  25 uL to obtain optimum Tm. For each 
pyrosequencing reaction, 20  ng of  bisulphite treated DNA 
in a volume of  2uL was used in a 25 uL reaction using the 
Qiagen Pyromark PCR kit under standard conditions with 
the observed Tm. Products were then cleaned and pyrose-
quenced on a Pyromark 96 ID machine using a 1:100 dilu-
tion of  20 uM sequencing primer. Percentage methylation 
values were calculated using standard default software set-
tings on the Pyromark Q-CpG software package. All reac-
tion plates were run with 100% methylated (generated with 
MSSl treatment of  genomic DNA) and unmethylated (gen-
erated by whole genome amplification using Qiagen Repli-G 
kit) DNA.
Statistical Analysis
To predict accuracy and other metrics in the identi-
fied markers, methylation data were exported to Stata 12.1 
(StataCorp, Texas, USA) as percentages. As methylation data 
were likely to be nonnormally distributed, a Wilcoxon rank 
sum test was performed on case-control data. To compare dif-
ferences between tissue types, analysis of variance (ANOVA) 
testing was carried out. To estimate test accuracy a logistic 
regression model using outcome (cancer/no cancer) as the 
dependent variable and using percentage methylation for each 
marker was used as the independent variables. Markers identi-
fied as significant (P < 0.05) were then subjected to a sensitivity 
analysis using ROC curves to identify a cutoff  of methylation 
to identify neoplasia to optimize sensitivity and specificity. This 
threshold was then modeled using the diagt function of Stata, 
correcting for a population prevalence of UC-associated dys-
plasia of ~3%.
RESULTS
Patients
For the discovery cohort, a cohort of 4 patients were 
obtained with tumor (adenocarcinoma) material and matched 
normal mucosa (Table 1), giving a total of 8 samples. A further 
4 samples of normal mucosa in patients with chronic UC were 
obtained, giving 12 samples that were run successfully on the 
HumanMethylation450 array. For the patients with UC-associated 
neoplasia 75% (3/4), patients were male with an average age of 
48 years. For the chronically inflamed normal mucosa, 50% (2/4) 
patients were male with an average age of 41 years. The duration 
of UC in these patients is shown in Table 1.
For the validation cohort, a total of  71 samples from 
71 patients were used. A decision was made to obtain a single 
sample from each patient to attempt to reduce bias. These sam-
ples were biopsy samples consisting of  acute colitis (n = 16), 
UC-associated cancer (n  =  11), chronic (>8  years) colitis 
(n  =  9), UC-associated dysplasia (n  =  9, all high grade dys-
plasia), normal mucosa downstream of neoplasia (n  =  19), 
and completely normal mucosa from unaffected controls 
(n = 7). The gender and age data of  these samples are shown in 
Table 2. To expand and enhance the dataset, we used Human 
Methylation450 array data from the TCGA (The Cancer 
Genome Atlas) project, with 245 cases of  colorectal cancer 
and 38 normal mucosa controls.
Differentially Methylated Positions (DMP)
A multilevel analysis of change in methylation was car-
ried out, assuming that methylation would change between 
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chronically inflamed mucosa, tumor-associated mucosa, and 
tumor itself  as part of a field effect. This analysis revealed 
12,412 diffferentially methylated probes with a Manzel- 
Haenszel adjusted Pvalue of < 0.05. The top 20 probes are 
shown in Table 3.
The top ranked CpG, cg08626004 (logFC  =  -4.32, 
B  =  8.97) lies within a CG-rich region of exon 5 of GNG7 
(G-protein subunit gamma 7), a membrane bound GTPase 
linked to 7-TM receptors. The next ranked CpG, cg03507241 
(logFC =  -0.31, B = 8.86) lies within the promoter region of 
TUBB6 (Tubulin Beta 6 class  V) that codes for a gene that 
acts as 1 of the tubulin scaffold components of microtubules. 
The third ranked CpG, cg025848557 lies within intron 1 of 
VAV3-AS1 (VAV3-antisense 1), a noncoding RNA. The fourth 
ranked CpG, cg03280624 lies within the promoter region of 
ZNF583, a zinc finger-related transcription factor. The fifth 
ranked CpG, cg12035092 lies within exon 1 of KIF5C, a kine-
sis heavy chain subunit. The sixth ranked CpG, cg12863545 lies 
within the promoter of PIK3R5, a PI3 kinase-related gene.
Differentially Methylated Regions
A similar analysis was carried out for diffentially methyl-
ated regions using the dmr.lasso function of ChAMP (Table 4) 
examing the differences between chronically inflamed mucosa, 
tumor-associated mucosa, and tumor itself. The top differen-
tially methylated region was within SGCE (Sarcoglycan epsi-
lon), a transmembrane protein that is a component of the 
dystrophin-glycoprotein complex. The second highest differ-
entially methylated region was within SOX2OT (SOX2 over-
lapping transcript), a long noncoding RNA that overlaps the 
coding region of the SOX2 gene and has been shown to regu-
late SOX2 expression.21, 22
Copy Number Variation
Copy number was called for all 12 samples successfully 
using the ChAMP package. In the tumor group, a recurrent 
deletion of variable length was seen at the very end of the 
q-arm of chromosome 5 in 3 out of 4 tumors (Chr 5:178017667-
180876320). This CNA is frequently seen in colorectal cancer, 
and has been reported at a high frequency in UC-related can-
cers.23 A recurrent variable length gain of the p-arm of chromo-
some 5 was also seen, which has also been previously reported 
in UC- associated cancer23
In agreement with previous studies, a diverse pattern 
of copy number alteration was seen in both normal mucosa 
downstream of a tumor and in matched chronically inflamed 
TABLE 2: Table of Validation Cohort
Summary Median Age Range Age Number of Samples Male:Female Pan:Left:Proc (U) Dur Med
Control 44 24–68 6 5:1 NA NA
Low Risk (Acute) 40 20–66 17 6:11 2:6:9 3
Intermediate (Chronic) 45 21–73 23 10:13 14:3:6 17
Field mucosa 57 38–78 19 15:4 11:2:1 (3) 11
UC-Dys 63.5 43–73 10 6:4 5:1:2 (2) 10
UC-Can 54 26–67 16 14:2 12:0:2 (2) 10
TABLE 1: Table of Recruited Patients to Study (MICROARRAY)
Code Sample Tissue Type Location Sex Age Group
1 DA1C Tumor Ascending colon M 38
2 DA3B Matched Hepatic Flexure M 38
3 DK1A Tumor Sigmoid M 33
4 DK3A Matched Transverse M 33
5 ES3B Tumor Descending M 72
6 ES2B Matched Transverse M 72
7 NBT1 Tumor Rectum F 50
8 NB2NA Matched Transverse F 50
9 8IBD33 Normal Descending M 38 or 28 Control (<1 yr)
10 9695 Normal Rectum M 51 Control (3 yr)
11 9693 Normal Rectum F 32 Control (6 yrs)
12 9730 Normal Rectum F 44 Control (<1 yr)
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mucosa. In the matched normal mucosa from downstream 
of the tumor, a recurrent copy number loss was seen in 3 out 
of 4 samples in chromosome 17q, localized to a 2 mb region 
(Chr17:40169693-41993127). In the chronically inflamed nor-
mal mucosa, recurrent chromosomal loss was seen in chro-
mosomes 1,2,6,10,11,17, 19, and 20 where recurrent loss was 
defined as >75% of samples.
Validation of Observed Methylation Changes
To validate changes seen in methylation, bisulphite pyrose-
quencing was carried out on the validation set of samples as 
described in methods. Based on the observed DMPs, the follow-
ing assays were designed: ZNF583, GNG7, PIK3R5, TUBB6, and 
KIF5C. An attempt was made to design a primer set to amplify 
VAV3, but this region was found to be very GC rich (GC content 
TABLE 3: Probe of Top Differentially Methylated CpGs Within Cohort Including Functions, Significance and Direction 
of Change (ID = Illumina Probe ID, Chr = Chromosome, logFC = log fold change, T = t-statistic, Pvalue = unadjusted 
P-value, adj.p.Val = adjusted Pvalue, B = Bayes Factor)
Rank ID Chr Gene logFC t PValue adj.PVal B
1 cg08626004 19 GNG7 -4.32 -12.2 7.92E-09 0.0011 8.97
2 cg03507241 18 TUBB6 -0.31 -13.5 2.62E-08 0.0013 8.86
3 cg25848557 1 VAV3 4.97 19.0 2.64E-09 0.0014 8.30
4 cg03280624 19 ZNF583 5.82 18.0 4.39E-09 0.0016 8.11
5 cg12035092 2 KIF5C 3.99 16.3 1.18E-08 0.0016 7.69
6 cg12863545 17 PIK3R5 4.15 15.5 1.89E-08 0.0017 7.47
7 cg00796360 19 ZNF583 4.05 15.1 2.46E-08 0.0017 7.35
8 cg24347663 2 ADD2 4.23 14.8 3.06E-08 0.0018 7.24
9 cg22260952 12 CHST11 3.38 13.9 5.63E-08 0.0024 6.93
10 cg23977631 2 LONRF2 4.75 13.4 7.67E-08 0.0025 6.76
11 cg13644629 19 ZNF549 4.22 13.3 8.30E-08 0.0025 6.72
12 cg26998044 17 PIK3R5 3.86 13.1 9.82E-08 0.0027 6.63
13 cg13916740 19 ZNF582 4.55 13.1 1.02E-07 0.0027 6.60
14 cg19538890 4 RNF150 2.91 9.3 2.38E-07 0.0312 6.58
15 cg27230784 17 LOC728392 3.82 13.0 1.08E-07 0.0027 6.57
16 cg27009208 19 ZNF583 4.72 12.9 1.12E-07 0.0027 6.55
17 cg23967742 10 CH25H 4.32 9.0 3.68E-07 0.0312 6.24
18 cg12936797 4 RNF150 2.67 8.8 4.33E-07 0.0312 6.12
19 cg08071282 16 TPSD1 -1.96 -8.5 6.70E-07 0.0312 5.78
20 cg06168875 19 NANOS3 -2.25 -8.5 6.84E-07 0.0312 5.76
TABLE 4: Table of Differentially Methylated Regions (DMR) from Methylation Array Data (Chr = Chromosone, DMR 
start – start position of DMR in base pairs, DMR End – end position of DMR in base pairs, DMR size = size of DMR in 
base pairs, DMR P = significance of DMR)
Rank Chr Gene DMR start DMR End DMR size DMR P
1 7 SGCE 94284472 94285349 878 2.96E-08
2 3 SOX2OT 181428147 181428730 584 5.74E-07
3 3 DGKG 186079969 186080309 341 6.14E-06
4 17 HOXB3 46650083 46653384 3302 6.79E-06
5 1 RXRG 165414114 165414644 531 1.67E-05
6 4 RNF150 142054752 142054884 133 1.79E-05
7 17 LOC404266 46681474 46683967 2494 2.08E-05
8 11 PTPRCAP 67204926 67206552 1627 0.000102554
9 6 LY6G6D 31684923 31686011 1089 0.000105019
10 17 LOC100133991 43339397 43339594 198 0.00011108
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>85%) making amplification very challenging and, therefore, fur-
ther study of this region was stopped. To simplify analysis, sample 
groups were consolidated into 2 groups for the purposes of the 
initial analysis, control (which included normal colon, acute col-
itis, and chronic colitis) and case (which included field mucosa, 
dysplasia, and cancer). Validation on the remaining panel demon-
strated nonsignificance on all markers in cases versus controls 
except TUBB6 (Table 5), which demonstrated a median methyla-
tion of 11% in controls (IQR 4) and 37% (IQR 42) in cases.
Further study of TUBB6 by tissue group demonstrated 
a significant (ANOVA P  =  0.0043, F  =  3.81) progression in 
methylation from normal mucosa, where methylation was at its 
lowest, through acute inflammation to dysplasia and neoplasia 
where methylation was as its highest (Fig. 1). Interestingly, meth-
ylation within the “field mucosa”, ie, the mucosa downstream of 
a dysplastic or neoplastic lesion also had increased methylation 
as compared to control suggesting a field effect in these patients. 
Due to limited sample material, we were unable to perform 
immunochemistry for TUBB6 expression to compare to methyl-
ation levels, however an analysis of the TCGA dataset for colo-
rectal cancer suggested no correlation between methylation and 
expression of TUBB6 (Supplementary figures 1).
Modeling of the association between TUBB6 methyl-
ation levels and presence of invasive disease (taken as either 
“field” mucosa, dysplasia, or cancer) using logistic regression 
found that a threshold of 17% methylation was sufficient to 
discriminate invasive disease correcting for a population pre-
velance of UC-associated dysplasia of 3% (AUC 0.84, 95% CI 
0.81–0.87), Supplementary figure 2. This gave a final post hoc 
test sensitivity of 70.1%, specificity of 98.6%, positive predic-
tive value of 60.3%, negative predictive value of 99.1% and a 
Youden index of 0.68.
CONCLUSIONS
In this study, we have carried out an exploratory analysis 
of the changes observed in methylation in tissue samples from 
patients with UC in the progression from normal mucosa, to 
disease associated “normal” mucosa, to dysplasia/neoplasia. 
We have then subsequently successfully validated differential 
methylation of TUBB6 as being a biomarker for progression 
in UC to invasive disease. To our knowledge, this is the first 
study that has utilized the power of epigenome-wide analysis to 
identify potential biomarkers of progression in UC . Abnormal 
methylation in cancer (both hyper- and hypomethylation) has 
been demonstrated to be adversely associated with survival 
across multiple cancer types.24–26
Our study has a significant weakness, such that the initial 
cohort consists of 4 patients with paired tumor and associated 
normal “field” mucosa with normal mucosa obtained from nor-
mal control mucosa. This could potentially lead to test inflation 
caused by small sample size leading to a high false discovery rate, 
and this probably accounts for our observation that 4 out the 5 
markers did not pass statistical validation. However, 2 of them 
- KIF5C and ZNF583 – only just did not reach significance and 
were therefore potential markers but were dropped because their 
observed methylation values included 0 values that would make 
test failures difficult to discriminate from true results.
However, our top ranked marker, TUBB6 validated in 
our independent cohort to a high significance level and demon-
strated its possibility as a potential biomarker for UC-associated 
dysplasia. This demonstrates that it is possible to demonstrate 
statistically significant biomarkers from small genome-wide 
datasets given careful statistical analysis, making this a cost 
effective way to perform these studies in other diseases.
The function of our identified markers remains obscure 
and ideally a biomarker should have a functional relevance to 
the disease being studied. Two genes that almost reached sig-
nificance―KIF5C and ZNF583―have functions not directly 
related to UC pathogenesis or progression. KIF5C (kinesin 
family member 5C) is a kinesin heavy chain subunit involved 
with protein trafficing within the central nervous system and 
has been linked to intellectual disability.27 Little is known of 
the function of ZNF583 (Zinc Finger 583) beyond its descrip-
tion as a zinc finger protein,28 making it presumably involved in 
transcriptional regulation.
TABLE 5: Table of Median Methylation in Genes to be 
Validated
Gene
Median  
Control (IQR)
Median Methylation 
Dysplasia (IQR)
Pvalue 
(Wilcoxon)
GNG7 75 (15.5) 77 (15.5) 0.86
KIF5C 2.5 (6) 0 (6) 0.05
PIK3R5 2 (8.5) 0 (10) 0.32
TUBB6 11 (4) 37 (42) <0.0001
ZNF583 2 (0.5) 5.5 (5.5) 0.06
FIGURE 1. Box plot of percentage methylation as determined by bisul-
phite pyrosequencing at TUBB6 by tissue type.
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TUBB6 codes for Tubulin beta 6, a tubulin scaffold pro-
tein associated with the formation of microtubules that are part 
of the cytoskeleton.29 A recent celluar genome-wide associated 
study highlighted the importance of differential expression30 of 
TUBB6 in the promotion of inflammatory cell death, known as 
pyroptosis. The study demonstrated that increased expression 
of TUBB6, in this case caused by an intragenic single nucleotide 
polymorphism, lead to decreased pyroptosis. This has potential 
associations with the mechanisms of cell death in UC , as defi-
ciencies in commensal-induced pyroptosis has been shown to 
increase the severity of UC in a murine model.31 Variable TUBB6 
expression has also been seen in other malignancies such as non-
small cell lung cancer32 and prostate, ovary, and breast cancer.33 
Some evidence has been demonstrated in cell lines by Mariani 
et al34 that TUBB6 expression is partially controlled by andro-
gen receptor status, with women showing higher expression of 
TUBB6 than men. However, our study is concerned with meth-
ylation of TUBB6 and the relationship between expression and 
methylation is complex and therefore it is difficult to understand 
whether there is an impact of gender on methylation of TUBB6 
as we have not shown any particular bias. Potentially deficient 
microtubules could be stabilized by an agent such as paclitaxel35 
offering a potential target for “high risk” colitis.
In conclusion, we have identified and validated a potential 
biomarker of UC-associated dysplasia in the form of abnormal 
methylation of TUBB6, identified by whole epigenome ana-
lysis. Further validation is essential and this marker will form 
part of a marker panel in the prospective clinical trial module 
of epigenetic biomarkers in the NIHR funded ENDCAP-C 
study.
SUPPLEMENTARY DATA
Supplementary data is available at Inflammatory Bowel 
Diseases online.
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